title: improved patency of transjugular intrahepatic portosystemic shunt: the efficacy of cilostazol for the prevention of pseudointimal hyperplasia in swine TIPS models.
abstract: OBJECTIVE
  To investigate the efficacy of oral administration of cilostazol to inhibit pseudointimal/intimal hyperplasia in swine TIPS models.
  
  
  METHODS
  Successful TIPS creation was carried out in 11 of 12 healthy young pigs (20-25 kg). In the treatment group (n = 6), both cilostazol and aspirin were administered daily, from the first day of TIPS creation. The control group (n = 5) was administered only aspirin. The animals were followed-up for 2 weeks and then killed. The specimen (including portal vein, hepatic parenchymal tract, hepatic vein, and inferior vena cava) and stents were carefully bisected in a longitudinal fashion. The control group was compared with the treatment group by means of a gross and histologic evaluation of the degree of pseudointimal/intimal hyperplasia in the shunt.
  
  
  RESULTS
  At the gross evaluation, the control group showed considerably more pseudointimal/intimal hyperplasia than the treatment group. Using microscopic evaluation, there was a statistically significant difference (p < 0.05) in the mean maximum pseudointimal/intimal hyperplasia thickness between the control group (2.97 +/- 0.33 mm) and treatment group (0.73 +/- 0.27 mm).
  
  
  CONCLUSIONS
  Oral administration of cilostazol may have been effective in reducing pseudointimal/intimal hyperplasia in swine TIPS models.
authors: Department of Diagnostic Radiology, Konkuk University Hospital, Konkuk University School of Medicine, Seoul, Korea. psw0224@kku.ac.kr
authors: Sang Woo
authors: SW
authors: Park
authors: In Ho
authors: IH
authors: Cha
authors: Chul Hwan
authors: CH
authors: Kim
authors: Hae Jeong
authors: HJ
authors: Jeon
authors: Jeong Hee
authors: JH
authors: Park
authors: Suk Joo
authors: SJ
authors: Hong
authors: In Sik
authors: IS
authors: Lee
mesh_terms: D000284:Administration, Oral; D000818:Animals; D001241:Aspirin / Q000494:pharmacology; D000077407:Cilostazol; D004195:Disease Models, Animal; D005343:Fibrinolytic Agents / Q000494:pharmacology*; D005352:Fibromuscular Dysplasia / Q000517:prevention & control*; D006503:Hepatic Veins / Q000187:drug effects / Q000473:pathology; D011169:Portal Vein / Q000187:drug effects / Q000473:pathology; D019168:Portasystemic Shunt, Transjugular Intrahepatic / Q000379:methods*; D013552:Swine; D013777:Tetrazoles / Q000494:pharmacology*; D014682:Vena Cava, Inferior / Q000187:drug effects / Q000473:pathology
chemical_list: D005343:Fibrinolytic Agents; D013777:Tetrazoles; D000077407:Cilostazol; D001241:Aspirin